The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.

Perceptive Credit Holdings has agreed to provide the company with the loan, which CareDx said it will use to repay outstanding debt.

The firm said it expects fourth quarter revenues of $12.3 million to $12.5 million, a year-over-year increase of 13 percent to 15 percent.

Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.

The firm, which said last week it expected to raise $15.9 million, has said it will use the net proceeds for working capital and general corporate purposes.

The company said it plans to use the net proceeds for working capital and general corporate purposes.

Piper Jaffray analyst William Quirk said the pricing, which was much higher than expected, will help push CareDx toward profitability.

The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today. 

The company said it will use the proceeds from the offering for working capital and general corporate purposes, among other things.

The final LCD covers AlloSure in renal allograft recipients who have a probability of active renal allograft rejection.


Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.